NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Royal Caribbean Group (NYSE: RCL), Mesoblast Limited (NASDAQ: MESO), Loop Industries, Inc. (NASDAQ: LOOP), and Turquoise Hill Resources Ltd. (NYSE: TRQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link

Royal Caribbean Group (NYSE: RCL)

Class Period: February 4, 2020 to March 17, 2020

Lead Plaintiff Deadline: December 7, 2020

The complaint, filed on October 7, 2020, alleges that throughout the Class Period defendants failed to disclose material facts about the Companys decrease in bookings outside China, instead maintaining that it was only experiencing a slowdown in bookings from China. The Action further alleges that defendants failed to disclose material facts about the Companys inadequate policies and procedures to prevent the spread of COVID-19 on its ships. The truth about the scope of the impact that COVID-19 had on the Companys overall bookings and the inability of Royal Caribbean to prevent the virus spread on its ships was revealed through a series of disclosures.

First, on February 13, 2020, Royal Caribbean issued a press release stating that it had canceled 18 voyages in Southeast Asia due to recent travel restrictions and further warning that recent bookings had been softer for its broader business.

On this news, Royal Caribbean shares fell over 3 percent.

Second, on February 25, 2020, Royal Caribbean filed its 2019 Form 10-K, indicating that COVID-19 concerns were negatively impacting its overall business.

On this news, Royal Caribbean shares fell over 14 percent.

Third, on March 10, 2020, Royal Caribbean withdrew its 2020 financial guidance, increased its revolving credit facility by $550 million, and announced that it would take cost-cutting actions due to the proliferation of COVID-19, further revealing that COVID-19 was severely impacting Royal Caribbeans 2020 customer booking and that its safety measures were inadequate to prevent the spread of the virus on its ships.

On this news, Royal Caribbean shares fell over 14 percent.

Fourth, on March 11, 2020, Royal Caribbeans largest competitor, Carnival, announced a 60-day suspension of all operations, prompting concern that Royal Caribbean would follow suit. At the same time, Royal Caribbean also cancelled two cruises, beginning a series of cancellations and suspensions to follow.

On this news, Royal Caribbean shares fell almost 32 percent.

Fifth, on March 14, 2020, Royal Caribbean announced a suspension of all global cruises for 30 days.

On this news, Royal Caribbean stock fell over 7 percent.

Sixth, on March 16, 2020, the Company revealed that global operations could be suspended longer than anticipated, announcing the cancellations of two additional cruises throughout April and into May.

On this news, Royal Caribbean shares fell over 7 percent.

Finally, on March 18, 2020, analysts downgraded Royal Caribbeans stock and slashed their price targets.

On this news, Royal Caribbean shares fell more than 19 percent.

For more information on the Royal Caribbean class action go to: https://bespc.com/cases/RCL

Mesoblast Limited (NASDAQ: MESO)

Class Period: April 16, 2019 to October 1, 2020

Lead Plaintiff Deadline: December 7, 2020

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial to treat children with steroid refractory acute graft versus host disease (aGVHD).

In early 2020, Mesoblast completed its rolling submission of its Biologics License Application (BLA) with the FDA to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD.

On August 11, 2020, the FDA released briefing materials for its Oncologic Drugs Advisory Committee (ODAC) meeting to be held on August 13, 2020. Therein, the FDA stated that Mesoblast provided post hoc analyses of other studies to further establish the appropriateness of 45% as the null Day-28 ORR for its primary endpoint. The briefing materials stated that, due to design differences between these historical studies and Mesoblasts submitted study, it is unclear that these study results are relevant to the proposed indication.

On this news, the Companys share price fell $6.09, or approximately 35%, to close at $11.33 per share on August 11, 2020.

On October 1, 2020, Mesoblast disclosed that it had received a Complete Response Letter (CRL) from the FDA regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that the Company conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD. The CRL also identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.

On this news, the Companys share price fell $6.56, or 35%, to close at $12.03 per share on October 2, 2020.

The complaint, filed on October 8, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that comparative analyses between Mesoblasts Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies; (2) that, as a result, the FDA was reasonably likely to require further clinical studies; (3) that, as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Mesoblast class action go to: https://bespc.com/cases/MESO

Loop Industries, Inc. (NASDAQ: LOOP)

Class Period: September 24, 2018 to October 12, 2020

Lead Plaintiff Deadline: December 14, 2020

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that Loops scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the companys process internally. The report also stated that Loops previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were technically and industrially impossible, according to a former employee. Moreover, the report alleged that Executives from a division of key partner Thyssenkrupp, who Loop entered into a global alliance agreement with in December 2018, told us their partnership is on indefinite hold and that Loop underestimated both costs and complexities of its process.

On this news, the Companys share price fell $3.78, or over 32%, to close at $7.83 per share on October 13, 2020.

The complaint, filed on October 13, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loops purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loops announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Loop class action go to: https://bespc.com/cases/Loop

Turquoise Hill Resources Ltd. (NYSE: TRQ)

Class Period: July 17, 2018 to July 31, 2019

Lead Plaintiff Deadline: December 14, 2020

Turquoise Hill is an international mining company focused on the operation and development of the Oyu Tolgoi copper-gold mine in Southern Mongolia (Oyu Tolgoi), which is the Companys principal and only material resource property. Turquoise Hills subsidiary, Oyu Tolgoi LLC, holds a 66% interest in Oyu Tolgoi, and the remainder is held by the Government of Mongolia.

Rio Tinto plc and Rio Tinto Limited are operated and managed together as single economic unit and engage in mining and metals operations in approximately 35 countries. Through their subsidiaries, Rio Tinto owns 50.8% of Turquoise Hill. A Rio Tinto subsidiary, Rio Tinto International Holdings, Inc. (Rio Tinto International or RTIH; and collectively with Rio Tinto plc and Rio Tinto Limited, Rio Tinto), is also the manager of the Oyu Tolgoi project, including having responsibility for its development and construction.

On July 31, 2019, Turquoise Hill issued a press release and Management Discussion & Analysis (MD&A) making further disclosures about the status of the project, including that Turquoise Hill took a $600 million impairment charge and a substantial deferred income tax recognition adjustment tied to the Oyu Tolgoi project, and that it suffered a loss in the second quarter. The next day, before the market open, Rio Tinto issued a release concerning in part the project status, including that it had also taken an impairment charge related to the Oyu Tolgoi project, of $800 million.

Following this news, on August 1, 2019, Turquoise Hills common stock price closed at $0.53 per share, down 8.62% from the prior days closing price of $0.58 per share.

The complaint, filed on October 15, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements and omitted to disclose material facts regarding the Companys business and operations. Specifically, defendants made false and or misleading statements and/or failed to disclose that: (i) the progress of underground development of Oyu Tolgoi was not proceeding as planned; (ii) there were significant undisclosed underground stability issues that called into question the design of the mine, the projected cost and timing of production; (iii) the Companys publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (iv) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what the Company had represented; and (v) Turquoise Hill would require additional financing and/or equity to complete the project.

For more information on the Turquoise Hill class action go to: https://bespc.com/cases/TRQ

About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit http://www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

See the original post here:
Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Royal Caribbean, Mesoblast, Loop Industries, and...

How many timeshave you been asked that age-oldholiday question:What are you thankful for this Thanksgiving?

Given a global pandemic thats taken so many from their loved onesand left so much sadness in its wake, but has also brought out incredible acts of sacrifice and kindness, how would you replythis year?

FLORIDA TODAY posed that question tofour locals: ateenager who's spent his senior year in isolation with his family. AGen X'er who helps feed the hungry. Ababy boomer who, at61, recently met his birth father. And anoctogenarian, whose pink-tinted hair reveals justa hint of her outgoing nature.

Their answers assure us that while our walk through this life may be very different from that of someone else,we're all walking toward some of the same goals taking care of each other. Good health. Food on the table. Enjoying"normal" moments, like a beach walk and hugging a pet. Treasuring family.

Meet Wesley Smith, Jeannette Harrell, Gabe Cenker and Larry Goodijohn.

And from all of us: Happy Thanksgiving.

Wesley Smith knows too wellthe daily struggle andeconomic nightmares thatso many people in his community are living.

He can see it on their faces, hear it in their voices, as the kitchen manager at the Central Brevard Sharing Center in Cocoa, which serves up to 150 meals sixdays a week out of a small, busy kitchen.

In a year that's left many people seeking aid for the first time, battered by job losses and other pandemic-fueled indignities, he thinks the least he can dois seethey get a meal and a smile.

So smile this 53-year-olddoes, the hint of it coming from behind the mask he wears as he and his colleagues turn out meal after meal. On Thanksgiving, he'll be part of the meal service at the center.

And hefeels blessed. Blessed to have his children and mom near. Tobe surrounded by co-workers who "never let you down." Blessed to be part of a mission, on Thanksgiving and every day, to get food and glimmers of hope to those who need a boost.

"For me, this is my everything," Smithsaid. "If you're having a bad day, I want you to be out there on the road and think, 'I can pick up something good at the Sharing Center.' And pick up your spirits, too."

Wesley Smith, the kitchen manager for the Central Brevard Sharing Center, says his faith has helped him get through hard times and is thankful for the opportunity to help others in need.(Photo: MALCOLM DENEMARK/FLORIDA TODAY)

A Philadelphia native who at one time was the chef at Wuesthoff Hospital, he's had his own struggles, personal and physical. Afew years ago, Smithwas walking with what's called a "spastic gait" like a robot, he said. The Navy veteran learned at the Veterans Administration that he had a tumor on his spinal cord and post-surgery, faced therapy to walk again. The scar from that surgery is covered by long dreads, which he grew when he thought he might have cancer.

"I said, 'I'll put a positive spin on it. I'll grow it long so maybe when I have chemo, I'll have something left.' The doctor told me it doesn't work like that," Smithsaid, laughing."I didn't have cancer, but I let it keep growing."

That kind of upbeat attitude endears Smith to his work family.

"When I think of Wesley, I think of a kind, loving person, who's a bright light in our organization," said David Brubaker, Sharing Center president and CEO. "He's been through so much, where he was literally learning to walk again, and to use his arms. And yet, you can always see that smile, even behind his mask. It shows in his eyes."

Wesley Smith, the kitchen manager for the Central Brevard Sharing Center, says his faith has helped him get through hard times and is thankful for the opportunity to help others in need.(Photo: MALCOLM DENEMARK/FLORIDA TODAY)

Smith'sfaith has onlygrown through hardtimes, pushinghim to continue serving othersand, in a tough year, maintain a positive attitude.

"Once I chose Jesus, God chose me," Smithsaid. "That allows me, through all the trials and tribulations I went through, to be more empatheticwiththe people who come here.

"I can leave my thing at the door. I try not to tell people what I wentthrough because it leaves their mouth on the ground, like, 'How are you sitting here in front of me?' It was through Jesus and God. You know, at one pointI couldn't lift a pan past my waist. I get goosebumps thinking about it.So for me to be able to giveto the people here ... a smile is the one thing that's free, and I give it to everybody."

At 83,Jeannette "Jan" Harrell isblunt about life and death.

The Sharpes residenthaspre-existing conditions that made the spread of COVID-19 over the past few months even scarier. It's been heartbreaking, she said, to read about deaths of people young and old.

Jeannette "Jan" Harrell, of Sharpes, with her dog, Max. When Jan had a bad fall this year, Max stayed with her for many hours until help arrived.(Photo: TIM SHORTT/ FLORIDA TODAY)

Then on Oct. 21, she had her own health scare, when, sick and weak, she sankto the bathroom floor around 5 a.m. With her Life Alert button and cell phone in the living room, she lay there for more than seven hours.

Her terrier, Max "my little love," she calls himsat near or beside her the entire time, barking off and on. Harrelllaughs nowabout looking at the toilet and thinking about how her daughter comes tohelp clean.

But she's serious about what she thought ofas she lay there, unable to gather the strength to stand: "I'm not scared to die ... but I want to live."

"I have three of the most beautiful children that I raised by myself without child support," she said. "I love them they're my best friends. I have a new great-grandchild, born in August. And then I have some of the best friends in the world, too. I love my little apartment ... I love my life."

A Florida native, Harrell's proud of her roots. Her great-grandfather was the first postmaster in Orlando. Harrell moved to Brevard County in 1960 from Daytona Beach to work for Pan Am and later, at Boeing, at Kennedy Space Center, retiring in January 2000. Her memories from the Space Center are strong and poignant, like seeing the Challenger explosion and thinking, "That's not right." She loved seeing the recent SpaceX night launch, a crewed mission that was "return to flight for me," she said. "It was wonderful."

Jeannette "Jan" Harrell, of Sharpes, with her dog, Max. When Jan had a bad fall this year, Max stayed with her for many hours until help arrived. Florida Today

Her lifeis as busy as she wants it to be. She gives rides to friends who no longer drive and runs her own errands. When life is "normal," as it's not in this far-from-normal year, she has lunch with friends with an occasional margarita.

But just a month before Thanksgiving, the life Harrellloves was, literally, on the line.

It happened so fast. After being sick in the night, falling and lying on the floor from 5 a.m. until around 1 p.m., Harrell was rescued after a neighbor came to check on her and calledEMT's, Her vitals were good, she said, once she was helped up, and she passed on going to the ER.

"Max even growled at the EMT's," she said. "That's how he is."

But aday later, she was sick again. This time, she went to the Rockledge Medical Center's ER, and was hospitalized for four days, with sepsis, low potassiumand COPD. The thought of COVID was not far from her mind, but she praised hospital staff for their care and concern.

Jeannette "Jan" Harrell, of Sharpes, with her dog, Max. When Jan had a bad fall this year, Max stayed with her for many hours until help arrived.(Photo: TIM SHORTT/ FLORIDA TODAY)

And back home on her couch, cuddling Max and surrounded by good neighbors, books, the TV that tunes her in to NASCAR, football and baseball... yes, she said. It's good to be alive. On Thanksgiving. On any day.

"I'm so grateful to the young couple next door, to the EMTs, to the hospital staff ...I didn't know I was that sick," Harrellsaid.

"I am not afraid of dying, but I am just not readyyet."

In 2017 and 2018, Gabe Cenkerhikedthe Appalachian Trail with his mother.

In 2019, the STEM-loving teentookcollege tours with his parents, visiting campuses including those at Yale and Princeton.

Then came COVID-19. Andmore isolation than most of uscould imagine, down to the prestigious summer programs hehad beenaccepted to going virtual. Even though the Rockledge teen isa veteran of homeschooling and Florida Virtual School,it's a sure bet this isnot the senior year Gabe was expecting or would have chosen.

Gabe Cenker, 17, is seen smiling just moments after opening a letter of acceptance from Penn State.(Photo: Jennifer Cenker for FLORIDA TODAY)

He's missed being part of the Rockledge Highrobotics team, which has just started online meetings to figureout the upcoming season: "I'm looking forward to that," he said. He can still do beach walks. Or play tennis. He and his dad, Dave, an engineer, recently took a socially distanced camping trip to Blue Springs State Park.

Gabe Cenker will graduate from high school in May 2021. A global pandemic changed his senior year, but it hasn't changed his focus on his future. Florida Today

But when quarantines and restrictions end,and he can roam aboutfreely, what's on the schedule for this bright and motivated teen?

You might just find him in the produce aisle.

"As much of anything at all possible. Not even with friends but just sort of stupid things, like being able to go to a grocery store," said Gable, wholl graduate from high school in May 2021.

"Just getting out and doing normal things again ... my family likesto go to Disney a lot. We'd go every month to try a different restaurant. Wereally enjoyed doing that. That's stopped, obviously, since COVID. I've been trying to come up withsome things to do throughout and it's like, 'No, can't do that because it's inside ...I'm not all that picky. I'll just beexcited to do really anything and everything that's normal."

Gabe Cenker, 17, pictured during a November 2020 camping trip with his father at Blue Springs State Park, has experienced a very different senior year than the one the teen might have expected.(Photo: Dave Cenker for FLORIDA TODAY)

Because of his deep thoughts and "old soul," Gabewas given the trail name "Deep Waters" bya fellow hiker on the Appalachian Trail, said his mother.

"He's so gifted, and he's always been involved in so many interesting subjects," said Jennifer Cenker, who taught for Brevard Public Schools before stepping backto homeschool her son.

"So he's missing his friends ...he's got a core group of five or six friends he's known all the way through in homeschooling. But he's come up with methods to be with them."

One of those ways: hitting the kitchen. Gabeand one of his best friends have cooked together online, fromchoosing recipes to shopping online and, via their laptops, comparing their culinary exploits as they cook for their families.

The forced isolation has given thisfamilya lot of time to talk about Gabe'sfuture and explore every career possibility: aerospace engineering? Meteorology? Geology?

And the always-studiousGabe is dual-enrolled at Eastern Florida State College, prepping, in virtual style, to head off to college however that turns out, online or in person.

He's modest about his accomplishments. He's thoughtful in his responses.He's grateful, this Thanksgiving, for all the possibilities ahead.

"I want to get into college and then figure out like exactly what I want," he said. "I know it's definitelyin the STEM area.

"It gets more interesting when you're at one of the schools. I got to see two of them, and we started looking at housing, where I'd live there if I were accepted, all that. Depending on how things are in the spring ... maybe another road trip."

Larry Goodijohn grew up in a loving home in Houlton, Maine,with his mother, two siblings and his adoptive father.

While he didn't knowhis birth father's identity, he had a good life. He graduated from the University of Florida, where he met his future wife, Laura, and is a recovery operations manager forJacobs Technology. AMerritt Island resident, he'sthe father of a son, Spencer, and a daughter, Kelly, and soon, he and Laura will be grandparents.

But life got even sweeter and the family bigger in 2019, when Spencer took a23andMe DNA test and learned he was 27% Jewish. Then, Goodijohndid his own test. He found some distant cousins. Then camethe call that changed his life, from a young man who turned out to be a nephew.

In short order, Larry was talking with that nephew's dad, one ofLarry's younger brothers by his birth father (that Jewish connection). Not long afterward, he was on the phone with that father, Gerald "Jerry" Kane who just happensto live in Florida, too.

Larry Goodijohn, 62, of Merritt Island is thankful that he has finally met his birth father, Geralrd "Jerry" King, 83. The two, who will celebrate their second Thanksgiving together this year, discovered each other through DNA testing, and had been living just a couple of hours apart for the past 14 years.(Photo: TIM SHORTT/ FLORIDA TODAY)

The two menmet in person for the first time in August 2019. The reunion? Going strong.

Father and son will marktheir second Thanksgiving together this year with COVID-19 precautions in a very small and safe familygathering. Their first Christmas together is up next. They had their first Father's Day together in June. In addition to the brother and sisterhe grew up with, Goodijohnhas three brothers and two sisters who are the children of Kane and Irene,his wife of 63 years. All the sibllingshavebeen "super-welcoming and loving," Goodijohn said, and he feels a strong biological connection.

Larry Goodijohn, 62, of Merritt Island, chats with his birth father, Jerry King, 83, on FaceTime. The two met for the first time in 2019.(Photo: TIM SHORTT/ FLORIDA TODAY)

So many firsts. So much joy. So manyjokes: Kane's a master at those, his son said.

"I didn't really expect to find my father," said Goodijohn, whose mother, Joyce, was happyfor his discovery.

"I figuredthere was a good chance he might not even be alive at this point, I thought maybe I could find a sibling that I didn't know. But it turns out he's been living in The Villages for 14 years.It's so wonderfulto find your dad and find out he's such a good person, thathe's really smart and funny and all those things you'd hoped for."

Jerry Kane, now 83, was 19 and in the Air Force when he dated Goodijohn's mother in Maine.Hemarried a few months after Larry would have been conceived in 1957, and had no idea that Goodijohn's mother had given birth to his child.

He and Irene were excited to welcomeGoodijohn's family into their already big brood.

"I think the best part of all of this was thatI mean, aside from the fact that I found that I have another son is that my other children took to him like he's been in their lives forever," Kane said.

"I didn't know how I was going to handle it at first. You know, one day you have five children and you wake up the next morning, you have six. Butwe were just so much at ease. And then, Larry and I discovered things about each other that were so similar ...what he did as a child, whatI didto make money. Wewere both business-minded, even when we were young. Plus the fact that it looks remarkably like my two youngest sons and myself."

Kane is proud of his oldest child, without a doubt.

"I give big kudos to his mom for handling things the way she did and and raising a really good son," he said.

Larry Goodijohn, 62, of Merritt Island is thankful that he has finally met his birthfather, Jerry Kane, 83. Florida Today

If people really do beam with happiness, Goodijohn isshootingsignals to faraway planets.

Laura Goodijohn teared up as her husband of 35 years chatted with his father on FaceTime recently, sharing that her "new" in-laws and Larry's siblings have been incredibly loving.

"Larry is happier than I can ever remember.I get really emotional when I talk about it," she said. "He's always wanted to know who his father was. Sofor him to find him and find that he is such a wonderful man, and he looks just like him ...I just want to say it's changed Larry's life."

The entire family is making up for lost time, Goodijohn said.

"I'm so thankfulfor being able to to get to know them," he said. "I couldn't imagine the story turning out better."

Contact Kennerly at 321-242-3692 or bkennerly@floridatoday.com. Twitter:@bybrittkennerlyFacebook: /bybrittkennerly

Read or Share this story: https://www.floridatoday.com/story/news/2020/11/24/year-loss-and-great-need-what-you-thankful-year/6127510002/

Visit link:
In a year of great loss, isolation and need, locals look to family, future this Thanksgiving - Florida Today

This article was originally published here

Am J Nucl Med Mol Imaging. 2020 Oct 15;10(5):257-264. eCollection 2020.

ABSTRACT

The practical application of dual-time-point-imaging (DTPI) technique still remains controversial. One of the issues is that current parameters of DTPI quantification suffer from some deficiencies, mainly limited sampling of the diseased sites by confining measurements to specific locations. We aimed to examine the correlation between the percent change from early to delayed scans in whole-bone marrow (WBM) 18F-FDG uptake, as measured by a CT-based method of PET/CT quantification, and response to treatment in multiple myeloma (MM) patients. Pre-treatment 18F-FDG-PET/CT scans of 36 newly diagnosed MM patients were collected in a prospective study at 1 h and 3 h post tracer injection (NCT02187731). A threshold algorithm based on bone Hounsfield units on CT was applied to segment and quantify WBM 18F-FDG uptake. Patients were separated into two treatment groups: high-dose therapy with autologous stem cell transplant (HDT) and non-high dose therapy (non-HDT). The International Response Criteria for MM patients was used to determine each patients response to treatment. In the HDT group, WBM 18F-FDG uptake increased significantly in patients that had a poor response to treatment, from a median of 1.31 (IQR: 1.13-1.64) at 1 h to a median of 1.85 (1.45-2.10) at 3 h. The median percent change was 37.77% (IQR: 23.47-46.4), with a range of 6.10-50.73 (P = 0.003). However, no significant change in uptake was observed in patients with a complete response (P = 0.24). The same trend was observed for the non-HDT group. WBM uptake of 18F-FDG assessed with dual-time-point imaging may have a role in predicting treatment response in MM.

PMID:33224622 | PMC:PMC7675111

View original post here:
Correlation of whole-bone marrow dual-time-point (18)F-FDG, as measured by a CT-based method of PET/CT quantification, with response to treatment in...

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will present data from more than 35 abstracts studying the use of Adaptives clonoSEQ Assay for minimal residual disease (MRD) assessment at the American Society of Hematology (ASH) virtual 62nd Annual Meeting and Exposition, December 5-8. clonoSEQ is the first and only U.S. Food and Drug Administration (FDA)-cleared assay for MRD assessment in chronic lymphocytic leukemia (CLL), multiple myeloma and B-cell acute lymphoblastic leukemia (B-ALL) and is widely available to clinicians and patients across the U.S.

We are thrilled to see so many investigators presenting clonoSEQ data at ASH this year, among the more than 300 ASH studies highlighting MRD data, significantly growing the body of evidence validating this tool as a critical measure of patient outcomes, said Lance Baldo, MD, Chief Medical Officer of Adaptive Biotechnologies. As innovation continues for the treatment of blood cancers with novel and highly targeted therapies that create deep and durable responses for patients, we see clinicians increasingly utilizing clonoSEQ to help guide day-to-day patient care.

Assessment of MRD is a way to directly detect and quantify remaining disease, even in the absence of symptoms, across a spectrum of blood cancers. A patients MRD status gives clinicians timely information about how a patient may be responding to treatment, so patients and providers can be in control when it comes to managing their disease and treatment decisions.

clonoSEQ, the first clinical application of Adaptives immune medicine platform, will be featured in 14 oral presentations and 23 posters at ASH. Data on clinical and research utility from studies, as well as findings based on real-world experience, will be presented across a range of cancers including multiple myeloma, ALL, CLL and non-Hodgkins lymphoma (NHL). These new data show a correlation between clonoSEQ MRD results and improved blood cancer patient outcomes, enhanced clinical decision-making, and potential savings to the healthcare system.

Additional data at ASH this year will highlight Adaptives immune profiling research tool, immunoSEQ, to quantitatively assess the immune response to novel therapies in development.

Key presentations include:

AbouttheclonoSEQ AssayThe clonoSEQ Assay is the first and only FDA-cleared assay for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment. clonoSEQ was initially granted De Novo designation and marketing authorization by the FDA for the detection and monitoring of MRD in patients with MM and B-ALL using DNA from bone marrow samples.InAugust 2020, clonoSEQ received additional clearance from theFDA to detect and monitor MRD in blood or bone marrow from patients with CLL.

The clonoSEQ Assay leverages Adaptives proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The assay provides standardized, accurate and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to therapy over time, monitor patients during remission and predict potential relapse. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ Assay in patients diagnosed with CLL, MM and ALL.

The clonoSEQ Assay is a single-site test performed at Adaptive Biotechnologies.In addition to its FDA-cleared uses, clonoSEQ is also available as a CLIA-validated laboratory developed test (LDT) service for use in other lymphoid cancers and sample types. For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visitwww.clonoSEQ.com/technical-summary.

About immunoSEQ Assay Adaptives immunoSEQ Assay helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology. The immunoSEQ Assay can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, the immunoSEQ Assay is used to ask and answer translational research questions and discover new prognostic and diagnostic signals in clinical trials. The immunoSEQ Assay provides quantitative, reproducible sequencing results along with access to powerful, easy-to-use analysis tools. The immunoSEQ Assay is for research use only and is not for use in diagnostic procedures.

About AdaptiveAdaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is natures most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

For more information, please visit adaptivebiotech.com and follow us on http://www.twitter.com/adaptivebiotech.

Forward Looking Statements This press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with theSecurities and Exchange Commissionfrom time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

MEDIA CONTACT:Beth Keshishian917-912-7195media@adaptivebiotech.com

ADAPTIVE INVESTORS:Karina Calzadilla201-396-1687

Carrie Mendivil, Gilmartin Groupinvestors@adaptivebiotech.com

Visit link:
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with...

A cancer patient who was given less than a two per cent chance of survival has beaten the odds thanks to a new treatment that alters patient's immune cells to recognise and fight cancer.

Troy Daley was the first person in Australia to trial CAR T-cell therapy to treat mantle cell lymphoma.

The 45-year-old's ordeal began when he discovered a lump in his groin during a shower in 2014 and went to his GP.

"The next thing I knew I was on the operating table having biopsies done and scans done," he said.

About a week later, he was diagnosed with Mantle cell lymphoma a rare type of non-Hodgkin lymphoma.

When Mr Daley was initially diagnosed, his GP told him there was a 98 per cent chance he would be dead within the next six months.

"Telling the family's probably the hardest thing I've ever had to do," he said.

"I had a bit of a slack night that night and the next day I woke up and decided I was too young to fall over and got the gloves on."

Mr Daley was admitted to the Lismore Base Hospital for chemotherapy and received a stem cell transplant in Brisbane, but the treatments were not match for the aggressive cancer.

"(It) came back pretty quick, within sort of six to eight months it was a bit of a shock to everybody," he said.

Mr Daley's haematologist, Dr Dan Scott said he was put on cancer drug Ibrutinib, which worked initially, but after two-and-a-half years his condition progressed.

The next step would have been a bone marrow transplant, but despite a world-wide pool of donors no suitable match could be found.

With almost all the options exhausted, Mr Daley was registered with a clinical trial being done at the Peter MacCallum Cancer Centre in Melbourne.

"It was at a stage where we've got to have a go at something," he said.

"We're not going to sit back here and let the gods come and get me."

CAR T-cell therapy is a new form of immunotherapy that uses specially altered T-cells to directly and precisely target cancer cells.

Loading...

Dr Scott said the CAR T-cell trial was used in conjunction with ibrutinib to treat Mr Daley's cancer.

"That's what's been exciting and different about Troy's case is he's had access to this therapy, which is relatively unusual in this disease," he said.

Dr Scott said the results have far exceeded expectations.

He said a recent PET CT scan showed "no evidence of lymphoma".

"We've also done a bone marrow biopsy recent where we look under a microscope and look for any evidence of residual lymphoma and there was no evidence in Troy's case," Dr Scott said.

A third test, which involves looking for traces of lymphoma beyond a microscopic level, has also come back clear.

"At this point in time the results are as good as we could have ever hoped for," Dr Scott said.

Mr Daley said the results were "10 times better" than anyone could have predicted.

"Within 28 days we've had more success than we've had in five years," he said.

"We don't exactly know what the future holds but at this stage, for what I've been through I couldn't be any better."

Continue reading here:
CAR T-cell therapy treatment helps cancer patient beat near impossible odds - ABC News

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON), Royal Caribbean Group (NYSE: RCL), Mesoblast Limited (NASDAQ: MESO), and Loop Industries, Inc. (NASDAQ: LOOP). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link.

Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON)

Class Period: May 10, 2017 to September 25, 2020

Lead Plaintiff Deadline: December 4, 2020

On September 25, 2020, the U.S. Securities and Exchange Commission (SEC) issued a cease and desist order against Precigen. The cease and desist order involved inaccurate reports concerning the companys purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary methane bioconversion (MBC) program. The order noted that the Company was primarily using significantly more expensive pure methane for the relevant laboratory experiments but was indicating that the results had been achieved using natural gas. The cease-and-desist order further stated that although the Company pitched the MBC program privately to numerous potential business partners over the course of 2017 and 2018 and [a] number of these potential partners performed due diligence on the MBC program including reviewing lab results and plans for commercialization. [The Company] has not yet found a partner for the MBC program.

The complaint, filed on October 5, 2020, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose to investors that: (1) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion platform instead of natural gas; (2) yields from natural gas as a feedstock were substantially lower than the aforementioned pure methane yields; (3) due to the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (4) the Companys financial statements for the quarter ended March 31, 2018 were false and could not be relied upon; (5) the Company had material weaknesses in its internal controls over financial reporting; (6) the Company was under investigation by the SEC since October 2018; and (7) as a result of the foregoing, defendants public statements were materially false and misleading at all relevant times.

For more information on the Precigen class action go to: https://bespc.com/cases/PGEN

Royal Caribbean Group (NYSE: RCL)

Class Period: February 4, 2020 to March 17, 2020

Lead Plaintiff Deadline: December 7, 2020

The complaint, filed on October 7, 2020, alleges that throughout the Class Period defendants failed to disclose material facts about the Companys decrease in bookings outside China, instead maintaining that it was only experiencing a slowdown in bookings from China. The Action further alleges that defendants failed to disclose material facts about the Companys inadequate policies and procedures to prevent the spread of COVID-19 on its ships. The truth about the scope of the impact that COVID-19 had on the Companys overall bookings and the inability of Royal Caribbean to prevent the virus spread on its ships was revealed through a series of disclosures.

First, on February 13, 2020, Royal Caribbean issued a press release stating that it had canceled 18 voyages in Southeast Asia due to recent travel restrictions and further warning that recent bookings had been softer for its broader business.

On this news, Royal Caribbean shares fell over 3 percent.

Second, on February 25, 2020, Royal Caribbean filed its 2019 Form 10-K, indicating that COVID-19 concerns were negatively impacting its overall business.

On this news, Royal Caribbean shares fell over 14 percent.

Third, on March 10, 2020, Royal Caribbean withdrew its 2020 financial guidance, increased its revolving credit facility by $550 million, and announced that it would take cost-cutting actions due to the proliferation of COVID-19, further revealing that COVID-19 was severely impacting Royal Caribbeans 2020 customer booking and that its safety measures were inadequate to prevent the spread of the virus on its ships.

On this news, Royal Caribbean shares fell over 14 percent.

Fourth, on March 11, 2020, Royal Caribbeans largest competitor, Carnival, announced a 60-day suspension of all operations, prompting concern that Royal Caribbean would follow suit. At the same time, Royal Caribbean also cancelled two cruises, beginning a series of cancellations and suspensions to follow.

On this news, Royal Caribbean shares fell almost 32 percent.

Fifth, on March 14, 2020, Royal Caribbean announced a suspension of all global cruises for 30 days.

On this news, Royal Caribbean stock fell over 7 percent.

Sixth, on March 16, 2020, the Company revealed that global operations could be suspended longer than anticipated, announcing the cancellations of two additional cruises throughout April and into May.

On this news, Royal Caribbean shares fell over 7 percent.

Finally, on March 18, 2020, analysts downgraded Royal Caribbeans stock and slashed their price targets.

On this news, Royal Caribbean shares fell more than 19 percent.

For more information on the Royal Caribbean class action go to: https://bespc.com/cases/RCL

Mesoblast Limited (NASDAQ: MESO)

Class Period: April 16, 2019 to October 1, 2020

Lead Plaintiff Deadline: December 7, 2020

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial to treat children with steroid refractory acute graft versus host disease (aGVHD).

In early 2020, Mesoblast completed its rolling submission of its Biologics License Application (BLA) with the FDA to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD.

On August 11, 2020, the FDA released briefing materials for its Oncologic Drugs Advisory Committee (ODAC) meeting to be held on August 13, 2020. Therein, the FDA stated that Mesoblast provided post hoc analyses of other studies to further establish the appropriateness of 45% as the null Day-28 ORR for its primary endpoint. The briefing materials stated that, due to design differences between these historical studies and Mesoblasts submitted study, it is unclear that these study results are relevant to the proposed indication.

On this news, the Companys share price fell $6.09, or approximately 35%, to close at $11.33 per share on August 11, 2020.

On October 1, 2020, Mesoblast disclosed that it had received a Complete Response Letter (CRL) from the FDA regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that the Company conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD. The CRL also identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.

On this news, the Companys share price fell $6.56, or 35%, to close at $12.03 per share on October 2, 2020.

The complaint, filed on October 8, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that comparative analyses between Mesoblasts Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies; (2) that, as a result, the FDA was reasonably likely to require further clinical studies; (3) that, as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Mesoblast class action go to: https://bespc.com/cases/MESO

Loop Industries, Inc. (NASDAQ: LOOP)

Class Period: September 24, 2018 to October 12, 2020

Lead Plaintiff Deadline: December 14, 2020

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that Loops scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the companys process internally. The report also stated that Loops previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were technically and industrially impossible, according to a former employee. Moreover, the report alleged that Executives from a division of key partner Thyssenkrupp, who Loop entered into a global alliance agreement with in December 2018, told us their partnership is on indefinite hold and that Loop underestimated both costs and complexities of its process.

On this news, the Companys share price fell $3.78, or over 32%, to close at $7.83 per share on October 13, 2020.

The complaint, filed on October 13, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loops purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loops announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Loop class action go to: https://bespc.com/cases/Loop

About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit http://www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

View post:
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop...

Background 18-F fluorodeoxyglucose (FDG) uptake in the liver was used as a reference to characterize a complete molecular response (CMR) using positron emission tomography/computed tomography imaging (PET/CT) in patients undergoing treatment for newly diagnosed multiple myeloma, according to findings published in the Journal of Clinical Oncology.1

In order to determine response to treatment in the setting of multiple myeloma, the bone marrow (BM) needs to be assessed and the presence of any extramedullary disease (EMD) needs to detected. While FDG-PET/CT has become the preferred imaging method for the detection of minimal residual disease (MRD) in both of these compartments following treatment, and is considered complementary to the use of flow cytometry for identifying MRD in the bone marrow, standardized FDG-PET/CT criteria are needed to define CMR after therapy.

To date, few indications to interpret FDG-PET/CT after therapy have been proposed or validated, the study investigators noted.

This study relied on data from imaging substudies of 2 randomized, open-label, multicenter, phase 3 clinical trials of 228 transplant-eligible patients with newly diagnosed multiple myeloma treated with modern-era regimens in which at least 1 arm of each study also underwent autologous stem cell transplantation (ASCT).2,3

Whole-body PET/CT, including skull, upper limbs, and femurs, was performed at diagnosis, after induction therapy, and at completion of treatment but prior to maintenance therapy, if administered.

In particular, BM metabolic state, focal lesions (FLs; number and metabolic state), and EMD (site, number, and metabolic state) were checked and reported. FDG uptake degree was visually quantied in the target lesion according to the 5-point Deauville scale (DS) adopted for PET scans in lymphomas (FL score [FS]) and in the BM out of FLs (BM score [BMS]), the study authors clarified. Semiquantitative measures of FDG uptake by the liver and mediastinal blood pool were also determined.

The primary objectives of these imaging substudies were to dene criteria for PET CMR after therapy (PET MRD denition) by testing the prognostic impact of such criteria on [progression-free survival (PFS)]. A secondary objective was to assess whether these criteria were associated with overall survival (OS).

A key finding of this study was that, compared with a FS and a BMS of 4 or higher, a FS and a BMS less than 4, which was lower than the DS score for the liver, were independently associated with prolonged PFS on multivariate analysis (FS: hazard ratio [HR], 0.60; 95% CI, 0.37-0.95; P =.030; BMS: HR, 0.50; 95% CI, 0.26-0.97; P =.041).

In addition, on multivariate analysis, FS and BMS less than 4 were also independent predictors of prolonged OS (FS: HR, 0.34; 95% CI, 0.16-0.70; P =.004; BMS: HR, 0.25; 95% CI, 0.10-0.66; P =.005).

On the basis of these results, we believe that reduction of FL and BM uptake lower than the liver (DS score below 4) can be proposed as the standardized denition of PET CMR after therapy within new PET response criteria, the study investigators stated.

Nevertheless, they cautioned that prospective clinical trials are needed to validate these results, and to evaluate whether there is concordance between CMR as determined by FDG-PET/CT and MRD in the bone marrow by flow cytometry.

References

Follow this link:
Toward the Development of Standardized FDG-PET Imaging Criteria to Characterize Response in Multiple Myeloma - Cancer Therapy Advisor

Big Market Research, one of the worlds prominent market research firms has released a new report on GlobalAnimal Stem Cell Therapy Market, The report expertise includes assessing new opportunities & sizing, identifying and evaluating complex global value chains (including key drivers, restraints and winning strategies). The report will help the vendor to strategize its positioning in the Animal Stem Cell Therapy Market projects around the globe. The detailed competitor profiling helped identify and understand the key strategies and growth drivers of its competitors. The report includes detailed profile of key competitors, pre/post launch surveys, go-to-market research, supplier selection surveys, industry demand/pain point surveys, pricing analysis, product testing, effectiveness studies, and product positioning studies.

The Animal Stem Cell Therapy Market research report includes:

The Animal Stem Cell Therapy Market report explore:

The Animal Stem Cell Therapy Market includes identification of important potential market demand, expected sale of these devices in the next 5 years, various price and demand sensitive scenarios were built to ascertain on the profitability of investing, customer analysis, and future price analysis.

Ask pdf sample copy of this premium research on Animal Stem Cell Therapy with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/4083483?utm_source=PRL&utm_medium=MWA

The Animal Stem Cell Therapy Market is also characterized by a highly complex value chain involving product manufacturers, material suppliers, technology developers, and manufacturing equipment developers. Partnerships between research organizations and the industry players help in streamlining the path from the lab to commercialization. In order to also leverage the first mover benefit, companies need to collaborate with each other so as to develop products and technologies that are unique, innovative and cost effective.

Several existing Animal Stem Cell Therapy Industry manufacturers, new start-ups as well as research organizations and universities are constantly coming up with innovative ideas. The Animal Stem Cell Therapy Market is expected to grow exponentially over the next five years with the emergence of new applications and cost competitive products.

Market players have been discussed and profiles of leading players including Top Key Companies:Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

Animal Stem Cell Therapy Market By Product Type 2019-2025:DogsHorsesOthers

Based on type, the global market is segmented into the following sub-markets with annual revenue for 2015-2025 (historical and forecast) included in each section.

Animal Stem Cell Therapy Market By Application 2019-2025:Veterinary HospitalsResearch Organizations

Based on application, the global market is segmented into the following sub-markets with annual revenue for 2019-2025 (historical and forecast) included in each section.

Talk to our Analyst / Ask for a discount on Animal Stem Cell Therapy:https://www.bigmarketresearch.com/request-for-discount/4083483?utm_source=PRL&utm_medium=MWA

The comprehensive competitive landscape section of the report contains detailed analysis of the trends in mergers and acquisitions, agreements and partnerships, new product launches and so on in the Animal Stem Cell Therapy Market. This information will be very useful for existing players as well as new entrants in any market.

Geographically,Animal Stem Cell TherapyMarket is further analyzed into regions and country level analysis:North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Animal Stem Cell Therapy market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, and growth drivers of by analyzing the historical overall data of the considered market segments.

You May Also Like Our Other Top Trending Reports:

Read More:https://www.bigmarketresearch.com/report/3767216/global-x-ray-security-scanner-sale-insights-market?utm_source=PRL&utm_medium=MWA

About Us:

Big Market Researchhas a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:Mr. Abhishek Paliwal5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect:+1-971-202-1575Toll Free:+1-800-910-6452E-mail:help@bigmarketresearch.com

Continued here:
Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2027 - re:Jerusalem

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Continue reading here:
The Canine Stem Cell Therapy Market To Move Away From Insipidness, Reach US$ 218.2 Mn - PRnews Leader

Global Stem Cell Therapy Market Research Report 2020 to 2026 segmented by product type, applications and offers complete details including recent trends, statistics, and growth factors. An in-depth study of leading market players, supply chain scenario, business strategies and development scenario is presented in this report. Various factors like growth scenario, value chain analysis, deployment status and Stem Cell Therapy industry landscape scenario are presented in this report. The forecast information related to Global Stem Cell Therapy industry scenario is portrayed in this report. Stem Cell Therapy Market report depicts the forecast details to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns.

Request Free Sample Report of Stem Cell Therapy Market Report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=PT

For in-depth analysis and thorough understanding, the report presents a demand for individual segment in each region. It demonstrates various segments B2B, B2C, C2C and sub-segments Manufacturing, Consumer Goods, Retail, Automotive, Food and Beverage, Other of the global Stem Cell Therapy market. The global Stem Cell Therapy market report explains in-depth about the quantitative as well as the qualitative scenario of the market. The global Stem Cell Therapy market report delivers the precise analytical information that explains the future growth trend to be followed by the global Stem Cell Therapy market, based on the past and current situation of the market. In addition, the global Stem Cell Therapy market report delivers concise information about the federal regulations and policies that may indirectly affect market growth as well as the financial state. The situation of the global market at the global and regional level is also described in the global Stem Cell Therapy market report through geographical segmentation.

The research on the Stem Cell Therapy market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Stem Cell Therapy market on the basis of end user, product type, application, and demography for the forecast period 2020-2025. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics. This report strategically examines the micro-markets and sheds light on the impact of technology upgrades on the performance of the Stem Cell Therapy market.

Browse complete Stem Cell Therapy report description and TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=PT

Global Stem Cell Therapy market is segmented based by type, application and region.Based on Type, the market has been segmented into:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on Application, the market has been segmented into:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Stem Cell Therapy Market research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers, and challenges. The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used expert techniques for analyzing the Stem Cell Therapy Market; it also offers an examination of the global market. To make the report more potent and easy to understand, it consists of infographics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

The research report on the global Stem Cell Therapy market offers a comprehensive analysis, synthesis, and interpretation of data gathered about the Stem Cell Therapy market from the number of reliable sources. In addition, the information has analyzed with the help of primary as well as secondary research methodologies to offer a holistic view of the target market. Likewise, the Stem Cell Therapy market report offers an in-house analysis of global economic conditions and related economic factors and indicators to evaluate their impact on the Stem Cell Therapy market historically. The report provides a broad segmentation of the market by categorizing the market into application, type, and geographical regions. The Stem Cell Therapy market report delivers the growth prospects as well as the current scenario of the market. In addition, to assess the market size, the global Stem Cell Therapy market report offers a brief outlook of the market by synthesis, study, and addition of data form the number of sources.

The research provides answers to the following key questions: What will be the size of the market and the growth rate for the forecast period? 2020- 2027? Which key driving forces will keep create more opportunities for the Stem Cell Therapy market in years to come? Which are the most prominent players operating in the Stem Cell Therapy market? What have been their winning strategies so far? Which trends from the yesteryears or the future are likely to shape the progress of the Stem Cell Therapy market across different regions? What are the threats and challenges that can act like a barrier and restrict the development of the Stem Cell Therapy market? What are the future opportunities for prominent market players?

Major highlights of the report: All-inclusive evaluation of the parent market Evolution of significant market aspects-Industry-wide investigation of market segments Assessment of market value and volume in past, present, and forecast years Evaluation of market share Study of niche industrial sectors Tactical approaches of market leaders Lucrative strategies to help companies strengthen their position in the market

For More Information or Query or Customization Before Buying, Visit at https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=PT

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more:
Stem Cell Therapy Market 2020 to 2025: Business Development Strategies and Top Manufacturers Analysis : Anterogen Co., Ltd. (South Korea), MEDIPOST...